A number of other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Kura Oncology from a hold rating to a buy rating and set a $21.00 target price on the stock in a research note on Wednesday, August 7th. ValuEngine raised shares of Kura Oncology from a buy rating to a strong-buy rating in a research note on Monday, June 17th. HC Wainwright reissued a buy rating and issued a $29.00 target price on shares of Kura Oncology in a research note on Friday, August 2nd. Deutsche Bank began coverage on shares of Kura Oncology in a research note on Thursday, July 18th. They issued a buy rating and a $28.00 target price on the stock. Finally, Wedbush set a $30.00 target price on shares of Kura Oncology and gave the company a positive rating in a research note on Monday, June 17th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $28.00.
NASDAQ KURA opened at $17.83 on Thursday. The stock has a market cap of $788.10 million, a P/E ratio of -10.37 and a beta of 2.51. The company’s 50-day simple moving average is $19.50 and its 200 day simple moving average is $16.90. Kura Oncology has a twelve month low of $10.20 and a twelve month high of $21.42. The company has a quick ratio of 23.50, a current ratio of 23.50 and a debt-to-equity ratio of 0.03.
In other Kura Oncology news, insider Antonio Gualberto sold 18,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $21.11, for a total value of $379,980.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.00% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. CWM LLC acquired a new position in Kura Oncology in the first quarter valued at about $25,000. Point72 Hong Kong Ltd acquired a new position in Kura Oncology in the second quarter valued at about $25,000. Meeder Asset Management Inc. boosted its position in Kura Oncology by 164.9% in the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after buying an additional 1,204 shares in the last quarter. Bank of Montreal Can boosted its position in Kura Oncology by 82,066.7% in the second quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock valued at $49,000 after buying an additional 2,462 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Kura Oncology by 599.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after buying an additional 2,420 shares in the last quarter. Hedge funds and other institutional investors own 70.76% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.